Latest News and Press Releases

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Jan. 08, 2023 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR :  Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage...

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 30, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...

New data indicates potential to expand the therapeutic window and improve safety compared to existing T-cell engagersTri-specific T-cell engager resulted in AML cell-specific cytotoxicity with minimal...

First clinical observation of tumor localized CD40 activation provided by MP0317No systemic or dose-limiting toxicities observed, a key parameter for CD40 agentsDose escalation remains ongoing with...

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) --  Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage...

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage...

Continued development of MP0317, with initial clinical data from Phase 1 study expected in the second half of 2022Initiation of Phase 1 study for MP0533 expected by year endContinued progression of...

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...